AEterna Zentaris Initiates Phase II Cancer Trial

AEterna Zentaris has reported that dosing of AEZS-108, a luteinizing hormone-releasing hormone or LHRH agonist linked to doxorubicin, has commenced in its Phase II trial in gynaecological cancers.

This open-label, non-comparative multi-center Phase II trial will treat up to 82 women with LHRH-receptor positive ovarian and endometrial cancerous tumors. The primary endpoint for the trial will be the partial or complete tumor response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) and/or Gynaecologic Cancer Intergroup (GCIG) guidelines. The trial is being conducted in 15 centers in Europe.

David Mazzo, president and CEO of AEterna Zentaris, said: “We believe that our approach targeting only patients with LHRH-receptor expressing tumors using doxorubicin is key to both potential increased individual patient safety and potential augmented clinical benefit, while ultimately providing us results that will be pivotal in formulating the next steps in the clinical development of this novel agent.”